BioSpace News Archive

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. Roger Crystal, will present a company overview at the Jefferies Virtual Healthcare Conference

NuVasive, Inc. announced that it intends to offer, subject to market and other considerations, $400.0 million aggregate principal amount of Convertible Senior Notes due 2023 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that management will present company overviews at the following conferences being held virtually

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that David Lacey, M.D. has joined the Company’s Board of Directors

Intersect ENT, Inc., announced that management will participate in a virtual fireside chat at the William Blair 40th Annual Growth Stock Conference.

Real-time glucose data and alerts of Eversense CGM users can now be remotely monitored by friends and family on Android or iOS operating system

Quotient Limited, a commercial-stage diagnostics company, announced the Company will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 9:00 a.m. ET.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management will review initial results from the ALLO-501 ALPHA Phase 1 trial in relapsed/refractory non-Hodgkin lymphoma on May 29, 2020 via a live webinar at 5:30 AM Pacific Time/8:30 AM Eastern Time.

Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the ASCO20 Virtual Scientific Program on Friday, May 29, at 1:00 p.m. PT. David M. Reese, M.D., executive vice president of Research and Development at Amgen,